EP0571597A1 - Procede de traitement d'etats arthropathiques aigus et chroniques chez l'homme et d'autres mammiferes - Google Patents

Procede de traitement d'etats arthropathiques aigus et chroniques chez l'homme et d'autres mammiferes

Info

Publication number
EP0571597A1
EP0571597A1 EP92925157A EP92925157A EP0571597A1 EP 0571597 A1 EP0571597 A1 EP 0571597A1 EP 92925157 A EP92925157 A EP 92925157A EP 92925157 A EP92925157 A EP 92925157A EP 0571597 A1 EP0571597 A1 EP 0571597A1
Authority
EP
European Patent Office
Prior art keywords
chondroitin sulfate
sodium chondroitin
effective amount
shark
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92925157A
Other languages
German (de)
English (en)
Other versions
EP0571597A4 (en
Inventor
Glen M. Hartung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ARTHRO RESEARCH AND DEVELOPMENT Corp
Original Assignee
ARTHRO RESEARCH AND DEVELOPMENT Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ARTHRO RESEARCH AND DEVELOPMENT Corp filed Critical ARTHRO RESEARCH AND DEVELOPMENT Corp
Publication of EP0571597A1 publication Critical patent/EP0571597A1/fr
Publication of EP0571597A4 publication Critical patent/EP0571597A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Definitions

  • the present invention is directed toward a method for treatment or prophylaxis of painful conditions, especially pain associated with degenerative conditions of both hard and soft tissues, by the administration of a pain relieving effective dose of an angiogenesis inhibiting effective amount of sodium chondroitin sulfates to animals of mammalian species, including humans, in a safe and efficient manner.
  • a pain relieving effective dose of an angiogenesis inhibiting effective amount of sodium chondroitin sulfates to animals of mammalian species, including humans, in a safe and efficient manner.
  • Osteoarthrosis usually has an insidious onset of pain, stiffness and reduced range of movement. It commonly affects one or only a small number of joints. Joint laxity develops with locking and aberration. Most often effected are the joints which have been used the most or previously effected by trauma or inflammatory processes. Such joints suffer the greatest damage. Thus, the weight-bearing joints of the hips and knees, the lumbar spine and first carpometacarpal joints are common victims of the disease.
  • rheumatoid arthritis The essential features of rheumatoid arthritis are cyclic pain and swelling of several joints with morning stiffness continuing for several weeks. It tends to affect the peripheral small joints symmetrically.
  • Other common inflammatory arthropathies include alkylosing spondylitis, psoriatic arthropathy, septic (suppurative) arthritis, Reiter's disease and gouty arthritis.
  • Other traumatic and non-traumatic joint injuries include synovitis, capsulitis and the like.
  • the loss of function is due to destruction of the major structural components of the joint, cartilage and bone, and subsequent loss of the proper joint anatomy. As a consequence of chronic disease, joint destruction ensues and can lead to irreversible and permanent damage to the joint and loss of function. Destruction of architecture of the joint may be mediated by angiogenesis. ANGIOGENESIS
  • Angiogenesis is the development of a network 'of blood vessels which typically would lead to a vascular bed capable of sustaining viable tissue. It is characterized by the directed growth of new capillaries toward a specific stimulus, many of which have been proposed. Angiogenesis is a necessary step. It has been implicated to play an important role in the pathophysiology (the establishment and development) of certain inflammatory conditions. In osteoarthritis, for instance, it is involved in the reinitiation of cartilage growth and mineralization. Also, the vascular proliferation appears to be important in the pathogenesis of rheumatoid arthritis. Semble et al.. J. Rheumat. 12; 237, 1985. Thus, the inhibition of a angiogenesis is a prerequisite objective to control/alleviate inflammatory conditions.
  • ANTI-INFLAMMATORY DRUGS the inhibition of a angiogenesis is a prerequisite objective to control/alleviate inflammatory conditions.
  • NSAIDs non-steroid anti-inflammatory drugs
  • U.S. Patent No. 4,640,912 to Haus an describes the use of chondroitin sulfate preparations in the treatment and reduction of incidence of pathological conditions ranging from cancer, bacterial infections, trauma, irritation or damage to the linings of the renal pelvis, ureter, urethra and bladder caused by placement of foreign objects, tubes or instruments into the renal pelvis, ureter, urethra and bladder or kidney.
  • chondroitin sulfates may limit or even eliminate the activities of accidental septic infections (i.e. caused by microbial invasion) . Since chondroitin sulfates are viscous, they restrict the movement and the flow of inflammatory products such as proteins and large molecules. DIMETHYL SULFOXIDE The use of dimethyl sulfoxide as an agent for enhanced tissue penetration of other substances is known in the art. It is, for example, described in great detail in U.S. Pat. No. 4,296, 104, No., 3,551,554, No 3.711,606 and No. 3,743,727.
  • Cartilage is one of few avascular tissues in the body.
  • a factor (molecule(s)) endowed with angiogenesis inhibitor activity may be present in mammalian cartilages.
  • Several fractions having such activity have been identified in and prepared from natural sources, including calf and shark. The latter became an especially attractive source since it has been observed that elasmobranchs such as sharks, in contrast to mammals and even bony fish and amphibians, rarely exhibit neoplasm. See Guenther et al.. Biochi . Biophys. Acta, 372. 321; 1974.
  • CDI cartilage-derived neovascularization inhibitor
  • the present invention relates to a method useful for effectively treating, relieving and preventing both acute and chronic pain, especially such pain associated with in lammation of both hard and soft tissues in animals of mammalian species, including humans in an efficient and patient-friendly manner.
  • the methods are very powerful and effectively inhibit both angiogenesis and collagenase activity.
  • the method entails administering a sterile and endotoxin free pharmacologically effective amount of sodium chondroitin sulfate derived from shark cartilage extract, preferably via systemic routes of administration such as, for example, parenteral routes.
  • Sodium chondroitin sulfate is a sodium salt of chondroitin sulfate C, sodium salt of chondroitin sulfate D (sodium salt of chondroitin polysulfate) or mixtures thereof.
  • Sodium chondroitin sulfates from shark cartilage may be blended with sodium chondroitin sulfates from a non-shark source, for example, a mixture of at least 60 wt % of sodium chondroitin sulfate derived from shark cartilage and up to 40 wt % of sodium chondroitin sulfates derived from a non-shark source. Because of its long duration of action, the claimed method is particularly well-suited for both systemic and local treatment.
  • the method of this invention may be used for treating individuals in need of such pain relieving treatment locally at a disease site, for example, via intra-articular injections or transdermal applications.
  • substantial improvement can be obtained in the efficacy of the treatment since the utilized mixture of sodium chondroitin sulfates, in terms of both angiogenesis inhibitory activity and collagenase inhibitor activity, is found to be up to 1000 times more potent on a milligram basis than the prior art compositions.
  • This invention also provides a method of transdermal topical patch drug delivery for the treatment both locally and systemically of painful conditions of soft and hard tissues.
  • This method entails administering a pharmacologically effective amount of sodium chondroitin sulfate derived from shark cartilage and dimethyl sulfoxide (DMSO) to enhance tissue penetration.
  • Sodium chondroitin sulfate (SCS) as used herein is a sodium salt of chondroitin sulfate C, sodium salt of chondroitin sulfate D (sodium salt of chondroitin polysulfate) or mixtures thereof.
  • a blend of sodium chondroitin sulfates from shark cartilage and sodium chondroitin sulfates from a non-shark source for example, at least 60 % by weight of SCS and up to 40 % by weight of non-shark SCS, preferably a mixture of from about 65 to about 95 wt % of sodium chondroitin sulfate C derived from shark cartilage and from about 5 to 35 wt % of sodium chondroitin sulfates derived from a non-shark source may be used to practice this invention.
  • the SCS preparation used in the present invention is a heterogeneous glycosaminoglycan preparation with peptide content.
  • the peptide is linked to the chondroitin sulfate and to the chondroitin polysulfate in specific linkage regions. See Seno, J.Biochem., 3., 953-6: 1978; see also Akiyama et al, Biochem. Biophys. Acta, 674. 289-96: 1981) .
  • the peptide is chemically bound to the chondroitin sulfate molecule.
  • the composition of the instant invention is sterile and free of endotoxin, and is pharmaceutically acceptable as an administrable drug preparation via parenteral routes.
  • Soil et al chondroitin sulfate is effective in their invention at all molecular weights, i.e in order of about 50,000 to 100,000 Daltons, depending on the source, if administered topically or directly to the aggrieved cells.
  • the blend contains at least 60 wt %, preferably from about 65 to 95 wt %, and more preferably about 95 wt % of shark cartilage sodium chondroitin sulfates and up to 40 wt %, preferably from 5 to 35 wt % of sodium chondroitin sulfates derived from a cartilage of non-shark- origin.
  • non-shark cartilage it is preferably mammalian cartilage, and more preferably bovine cartilage.
  • the non-shark source is selected from bovine trachea and bovine nasal septa.
  • a highly purified chemical grade blend of shark sodium chondroitin sulfate (70 wt %) and bovine sodium chondroitin sulfates (30 wt %) is now commercially available.
  • This blend of SCSs is most useful for treating both acute and chronic painful conditions of both hard and soft tissues where an inappropriate development of capillary vessels leads to further progression of degenerative conditions (i.e., degenerative joint diseases, rheumatic diseases, etc.).
  • the representative examples of soft tissue injury include sprains and strains of ligaments, tendons, and muscles.
  • Degenerative joint disease is an example of a hard tissue injury.
  • chondroitin sulfates (SCS) derived from shark cartilage, preferably from shark fin, is superior to lower molecular weight sodium chondroitin sulfates derived from shark skin and vertebral column and from mammalian cartilage in terms of both analgesic and anti-angiogenesis properties.
  • SCS sodium chondroitin sulfates
  • Shark fin derived SCS is predominantly sodium chondroitin sulfate C (SCS-C) or sodium chondroitin sulfate D (SCS-D) (also known as sodium chondroitin polysulfate) which is a polysulfated form of sodium chondroitin sulfate C.
  • the molecular weights of chondroitin sulfates extracted from shark fin cartilages which are effective in the present invention ranges from 18,000 to 104,000 Daltons.
  • the fractions comprising chondroitin sulfates having a molecular weight of at least 40,000 are used to practice the invention.
  • the fractions having a molecular weight in the range from 40,000 to 55,000 Daltons are especially preferred. It has been found that the higher molecular weight coincides with a higher viscosity and a more concentrated presence of angiogenesis inhibitor peptide and a greater number of SCS molecules per weight unit of raw material.
  • the composition a) is a potent inhibitor of collagenase and proteolytic enzymes; b) protects cellular membranes from enzymatic degradation; c) stimulates chondrocytes and synoviocytes to produce high molecular weight sulfated and non- sul ates glycosaminoglycans; d) is a powerful scavenger of oxygen-derived free radicals; e) causes a sharp decline of proinflammatory mediators , i.e., PGE-2, LTB-4, LTC-4, and the like, in inflammatory exudates; f) is a potent angiogenesis factor inhibitor which suppresses the hyperproliferation and migration of capillary endothelial cells in and around damaged cartilage and subchondral bone; incidentally in the normal state these structures are essentially avascular and they become abnormally hypervascularized as degenerative arthritic conditions progress
  • a powdered form of a highly purified chemical grade preparation of shark cartilage is commercially available.
  • One of the identified manufacturers of the highly purified chemical grade preparation of shark cartilage is Calbiochem Behring Corp., LaJolla, California. This commercial preparation has been used in various chemical processes such as a process for -li ⁇ the selective extracorporeal precipitation of low-density lipoprotein described in U.S. Patent 4,908,354 to Seidel et al.
  • an extract containing 99.5 % of a mixture of sodium chondroitin sulfate C and sodium chondroitin sulfate D, and a highly purified chemical grade blend of shark sodium chondroitin sulfates (70 wt %) and bovine sodium chondroitin sulfates (30 wt %) are commercially available.
  • a stock solution of ten percent weight/volume is prepared by dissolving the shark cartilage extract sodium chondroitin sulfates in sterile water for injection USP.
  • the stock solution is then sterilized initially by filtration- through a series of suitable microporous filters.
  • these membranes Preferably, these membranes have an absolute pore rating in the range from about 0.22 micrometer to about 0.5 micrometer. Most preferably, 0.22 micron disk filters manufactured by and commercially available from Millipore Corporation, Bedford, MA are used.
  • the sterile solution is collected into a sterile evacuated container, preferably glass.
  • endotoxin free still may contain up to 0.5 g/ml of endotoxin, as allowed by the FDA standards upon meeting the standards of the pyrogen-free test (endotoxin test) .
  • endotoxins are removed by filtering the sterile stock solution through endotoxin removing filters. It has been found by the present inventor that by utilizing a series of endotoxin removing filters, preferably Pall Posidyne filters, one is able to ultrapurify the commercially available product from residual endotoxin contamination. The inventor has further found that a minimum of five (5) filters in succession is necessary to obtain suitable preparations. The resultant solution is both sterile and endotoxin-free.
  • Nylon microporous filter membranes which may be used in the endotoxin removal step are commercially available.
  • suitable filter membrane is manufactured by the cocasting process and available from Pall Corporation, Biosupport Division, of Glen Cove, New York, under the trademark SCF or the trademark Set SAVER, or the trademark N66 Posidyne.
  • a matrix of Nylon 66 is modified and functionalized with a high density of positively charged groups on its surface, typically by the addition of quaternary a ine groups.
  • a high concentration of these cationic functional groups at the pore surface of the material displays a little variation in a positive z ta potential in both acidic and basic solutions over a wide pH range and is preferably designed to remove a variety of substances including endotoxin, i.e., toxins produced as a result of bacterial growth or decomposition. See Degen, et al., U.S. Patent 4,702,804.
  • the foregoing filter materials are illustrative of suitable positively charged matrices that may be used in preparing stock solution for use in the pharmaceutical composition of this invention.
  • Any suitable microporous polymeric membrane may be used.
  • the criteria for selecting the filter include, for example, the requisite porosity, ability to withstand sterilization techniques, including gamma ray radiation, and charge capability for effectively removing endotoxin.
  • the stock solution may be passed through one or more filters.
  • a series of at least five 0.22 micron Pall brand PosidyneTM endotoxin removing filters are used to practice this invention.
  • compositions containing the active analgesic fractions for treatment of pain may be internally administered to a living animal body in any one of various ways, for example, parenterally in the form of sterile solutions or suspensions and in some cases intravenously in the form of sterile solutions.
  • the active ingredient i.e. sodium chondroitin sulfate C, D or mixtures thereof is incorporated in a suitable carrier, illustratively a pharmaceutical carrier, i.e., water, saline, and the like.
  • a suitable carrier i.e., water, saline, and the like.
  • the compositions of the invention may be produced by any of the following general methods.
  • compositions of the invention are prepared by simply mixing the endotoxin-free fractions as described above with known pharmaceutically acceptable carrier(s) by any art-known method.
  • compositions of the present invention are prepared by admixing DMSO with the endotoxin-free composition.
  • pharmaceutical compositions containing both SCS and DMSO have greater effectiveness than could be predicted by combining (in additive fashion) the known or theoretical effectiveness of the individual agents. It has been found, for example, that the addition of dimethyl sulfoxide (DMSO) in amounts of from about 50 to 99 % by weight, and preferably from about 90 to 99 weight percent, to sodium chondroitin sulfates composition will significantly enhance the penetration of the SCS into the blood stream. Additional information concerning the effectiveness of DMSO in transporting large molecules (high-molecular weight molecules) through the intact skin may be found, for example, in Remington's Pharmaceutical Sciences, 15th Edition.
  • DMSO dimethyl sulfoxide
  • compositions are formulated as dosage units, each unit being adapted to supply a fixed dose of active ingredient(s) .
  • Unit ampules and prefilled syringes are examples of preferred dosage forms, however, the composition may be offered in multiple-dosage containers and the like.
  • Each unit dose will contain an amount of SCS effective to inhibit angiogenesis. It is only necessary that the active ingredient constitutes an effective amount, i.e., such that a suitable dosage will be consistent with the dosage form employed.
  • the exact dosages, as well as daily dosages for the subject may vary depending on whether the subject is human or animal and according to such factors as age, sex, extent of the disease, and so forth, but for instance in horses, usually a therapy is initiated by administering intramuscularly a one time loading dose of about 1,000 mg, followed 48-96 hours later with a maintenance dosage of about 500 mg (intramuscularly) every 48-96 hours, based on the individual response.
  • the daily parenteral dosage for a sexually mature human subject is from 0.5 mg to 2.0 milligrams per kg of body weight, with from 0.5 to 1 milligram per kg of body weight being preferred per unit dose.
  • the SCS containing composition used herein is safe and efficacious in remission of painful inflammatory conditions and other painful conditions.
  • Acute, subacute and chronic administration of the composition in horses revealed no signs or symptoms of toxicity even at dosages exceeding six times the recommended dose (up to 3,000 mg) administered for fourteen (14) weeks.
  • Peak plasma levels of the composition are achieved within one to two hours following a single intramuscular injection, although there may be considerable individual variations.
  • Plasma half-life and analgesic activity may reflect factors such as protein binding, organ uptake and concentration of the active agent in analgesic exudates.
  • the active agents of the invention may be combined with other pharmacologically active agents, or with buffers or the like for administration as long as the antagonistic effect is avoided.
  • the proportions of these agents in the composition may vary widely.
  • the parenteral dosage forms may be injected by the subcutaneous, intramuscular, intravenous or intra-articular routes.
  • the composition is administered in solution or suspension and its dosage may include any conventional injectable solutions together with pharmaceutically acceptable preservatives and buffers. .
  • the chondroitin sulfates are present at a final concentration of about 10 % (wt/vol) in a pharmaceutically acceptable vehicle.
  • the preferred concentrations of the chondroitin sulfates are in the range from about 10 to 25 % (wt/vol) .
  • Preferred daily dose levels in mammals would be up to 1 mg/kg of mammalian body weight.
  • the SCS-containing composition may also be provided in powder form which is redissolved before use in a suitable vehicle, for instance, sterile, endotoxin free water or saline.
  • a suitable vehicle for instance, sterile, endotoxin free water or saline.
  • administering an effective dose of SCS alone or in combination with DMSO according to the present invention is an effective method for reducing pain associated with inflammatory and other painful conditions.
  • Applicant has found that an inflammatory or other painful conditions may be successfully treated by applying to the skin a mixture of sodium chondroitin sulfate and dimethyl sulfoxide in amounts effective to ameliorate the inflammation when applied to an area of the skin proximate to the inflammation.
  • the method which utilizes a dimethyl sulfoxide-sodium chondroitin sulfate transdermal topical patch drug delivery system has been found to be effective for the treatment of painful inflammatory conditions of soft and hard tissues, both locally and systemically.
  • the preferred form of the topical patch delivery system contains a mixture of sodium chondroitin sulfate(s) combined with dimethyl sulfoxide in a ratio of from about 1:1 to about 1:15 by weight.
  • a more preferred form of the topical patch drug delivery system contains about 10 wt % of the mixture of sodium chondroitin sulfate and about 90 wt % of DMSO.
  • the patch is applied to a shaved, clean and non-irritated area of skin and changed every 96 hours.
  • the contained mixture is slowly released and penetrates the skin to deliver both local and systemic medication.
  • the ingredients act together to achieve a synergistic result more effective than can be obtained from both agents individually, and more effective than could be predicted from the mere, addition of the known efficacies of the individual ingredients.
  • the method of the present invention provides effective symptomatic relief for individuals suffering from arthritic disease, pain associated inflammatory conditions, or other painful conditions. It is believed that in many instances, true remission of these diseases will be achieved.
  • Each of these horses was administered an initial loading dose of 1000 mg of a blend of about 70 wt % of sodium salt of chondroitin sulfate C derived from shark cartilage and about 30 wt % of sodium salt of chondroitin sulfates derived from bovine nasal septa/trachea via the intramuscular route.
  • This preparation was purchased from SKK - Japan and further purified to remove endotoxin as previously described. The animals were examined twenty-four (24) hours later and a response was evaluated.
  • a favorable response was based on a three (3) point improvement seen after 24 hours from the drug administration. Rating of the improvement was based on the degree of local signs and symptoms of pain, including local heat, swelling, tenderness and range of motion.
  • PSGAG Adequan i.m. ; a product of Luitpoid
  • compositions given in a single injection produce consistent, significant analgesic activity as evidenced by favorable response rate of 82 % when given in the claimed doses.
  • This example is not intended to limit or restrict the scope of the invention in any way, and should not be construed as providing dosage forms, regimens and methods of administration which must be utilized exclusively to practice the invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Procédé de traitement d'états inflammatoires chez les mammifères, y compris l'homme et le cheval, au moyen de l'administration auxdits mammifères d'une quantité efficace de sulfate C-chondroïtine de sodium, de sulfate D-chondroïtine de sodium ou de leurs mélanges, essentiellement exempts d'endotoxine. On peut éventuellement mélanger le sulfate C-chondroïtine de sodium, le sulfate D-chondroïtine de sodium ou leur mélange avec 40 % en poids maximum de sulfates-chondroïtine de sodium dérivés de la trachée et de la cloison des fosses nasales de bovins. On peut administrer lesdites préparations par voie parentérale, intrasmusculaire ou transdermique.
EP19920925157 1991-11-15 1992-11-16 Method for treatment of acute and chronic painful arthropathic conditions in human and other mammals Withdrawn EP0571597A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79260791A 1991-11-15 1991-11-15
US792607 1991-11-15

Publications (2)

Publication Number Publication Date
EP0571597A1 true EP0571597A1 (fr) 1993-12-01
EP0571597A4 EP0571597A4 (en) 1994-06-01

Family

ID=25157479

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19920925157 Withdrawn EP0571597A4 (en) 1991-11-15 1992-11-16 Method for treatment of acute and chronic painful arthropathic conditions in human and other mammals

Country Status (3)

Country Link
EP (1) EP0571597A4 (fr)
CA (1) CA2100657A1 (fr)
WO (1) WO1993009766A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6380366B1 (en) 1994-04-28 2002-04-30 Les Laboratoires Aeterna Inc. Shark cartilage extract:process of making, methods of using and compositions thereof
US5888984A (en) 1994-05-12 1999-03-30 Dermal Research Laboratories, Inc. Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
WO1998040088A1 (fr) 1997-03-11 1998-09-17 Les Laboratoires Aeterna Inc. Compositions pour traiter les tumeurs, contenant des extraits de cartilage de requin et des agents antineoplastiques
US7906153B2 (en) 1998-04-08 2011-03-15 Theta Biomedical Consulting & Development Co., Inc. Anti-inflammatory compositions for treating multiple sclerosis
US6984667B2 (en) * 1998-04-08 2006-01-10 Theta Biomedical Consulting And Development Co. Synergistic proteoglycan compositions for inflammatory conditions
US6168807B1 (en) 1998-07-23 2001-01-02 Les Laboratoires Aeterna Inc. Low molecular weight components of shark cartilage, processes for their preparation and therapeutic uses thereof
WO2000044367A2 (fr) 1999-02-01 2000-08-03 Dermal Research Laboratories, Inc. Composition pharmaceutique d'hydrates de carbone complexes et d'huiles essentielles et methode d'utilisation de celle-ci
US6083933A (en) * 1999-04-19 2000-07-04 Stellar International Inc. Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution
ES2167251B1 (es) * 2000-07-13 2003-09-16 Bioiberica Nuevos disacaridos con accion antiartrosica.
US7879824B2 (en) 2001-07-31 2011-02-01 Dermal Research Laboratories, Inc. Methods of preventing or treating diseases and conditions using complex carbohydrates
JP4754066B2 (ja) * 2000-12-22 2011-08-24 株式会社林原生物化学研究所 抗関節障害剤
DE60212542T2 (de) * 2001-10-12 2007-06-21 Nipro Corp., Osaka Injektionslösung enthaltend ein Kolloid aus Eisen und Haiknorpel-Chondroitinsulfat
JP2003335698A (ja) * 2002-05-20 2003-11-25 Maruha Corp 高尿酸血症治療又は予防用組成物
US20040132689A1 (en) * 2002-12-27 2004-07-08 Seiji Nishida Aqueous preparation containing a shark-derived chondroitin iron sulfate colloid
US20040161476A1 (en) 2003-02-19 2004-08-19 Hahn Sungtack Samuel Cystitis treatment with high dose chondroitin sulfate
FR2867981B1 (fr) * 2004-03-24 2008-10-31 Genevrier Sa Lab Utilisation des chondroitine mono-et disulfates en therapeutique
ES2327480B1 (es) * 2007-06-15 2010-08-10 Bioiberica, S.A. "disacaridos para el tratamiento de tendones, ligamentos y huesos".

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4473551A (en) * 1982-08-23 1984-09-25 Faxon Pharmaceuticals, Inc. Anti-inflammatory composition

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FORSTSCHR.MED. vol. 100, no. 35 , 1982 pages 1624 - 27 *
PRAXIS vol. 66, no. 52 , 1977 pages 1696 - 99 *
See also references of WO9309766A1 *
'The Merck Index, 11th Ed.' 1989 , MERCK & CO. INC. , RAHWAY, N.J., USA * 2217: Chondroitin sulfate * *
THERAPIEWOCHE vol. 31, no. 43 , 1981 pages 7137 - 49 *
THERAPIEWOCHE vol. 33, no. 33 , 1983 pages 4238 - 44 *

Also Published As

Publication number Publication date
EP0571597A4 (en) 1994-06-01
WO1993009766A1 (fr) 1993-05-27
CA2100657A1 (fr) 1993-05-16

Similar Documents

Publication Publication Date Title
EP0571597A1 (fr) Procede de traitement d'etats arthropathiques aigus et chroniques chez l'homme et d'autres mammiferes
AU655935B2 (en) Pharmaceutical composition of florfenicol
US3966908A (en) Method of treating degenerative joint afflictions
CA2078221C (fr) Compositions pharmaceutiques comprenant de la taurolidine et/ou du taurultam
US4604391A (en) Treatment of osteitis and osteomyelitis employing thiadiazine compounds
RU2001116077A (ru) Способ лечения церебральных ишемий, а также применение эритропоэтина или производных эритропоэтина для лечения церебральных ишемий
JPH08501317A (ja) 抗菌性インターフェロン誘発性医薬品
KR102285724B1 (ko) Dna 단편 혼합물 및 히알루론산을 포함하는 연골 재생용 조성물
WO1991002529A2 (fr) Produit et methode pour tuer les cellules anormales chez les vertebres
AP619A (en) Use of hyaluronic acid or salt for the treatment of a human having a stroke or myocardial infarction.
US8598144B1 (en) Method of administering hyaluronan formulation for the amelioration of osteoarthritis
DE69531166T2 (de) Arzneistoff zur erleichterung der durch immunsuppressiva verursachten nebenwirkungen
RU2008126108A (ru) Фармацевтическая композиция для лечения остеоартрита, содержащая клодроновую кислоту и гиалуроновую кислоту
RU2349339C1 (ru) Средство, обладающее иммуномодулирующим, антивирусным, антибактериальным, антиоксидантным, мембраностабилизирующим, стимулирующим регенерацию хрящевой и соединительной ткани свойствами
KR20220152904A (ko) Dna 분획물 및 콘드로이틴 설페이트를 포함하는 관절염 예방 또는 치료용 조성물
DE69332904T2 (de) Hemmung von hiv-infektion
KR100266929B1 (ko) 약학적 라이신-함유 폴리펩티드 조성물 및 그의 사용방법
US6218433B1 (en) Use of pharmaceutical composition in the treatment of traumatic arthritis in horses
FR2580175A1 (fr) Utilisation therapeutique nouvelle de l'urogastrone humaine
US12059430B2 (en) Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions
US20070178161A1 (en) Use of n-acetryl-d-glucosamine in treating and controlling non-specific inflammations caused by physical or chemical factors
RU2228742C2 (ru) Способ лечения рецидивирующего иридоциклохориоидита лошадей
US5409901A (en) Therapeutic compositions comprising nucleoproteins as the active agents, and methods of producing and using such compositions
CN104435043A (zh) 一种治疗关节炎引起的关节疼痛的药物及其制备方法
JPS62252729A (ja) 造血機能回復促進剤

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

17P Request for examination filed

Effective date: 19931111

A4 Supplementary search report drawn up and despatched
AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 19941121

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19950503